Expand ACTU Menu
ACTU MENU

ACTU Latest Press Releases

-- March 24, 2026 --

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers ACCESS Newswire 7:00 AM

-- March 9, 2026 --

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors Globe Newswire 8:45 AM

-- March 4, 2026 --

Actuate Therapeutics to Present at The Citizens Life Sciences Conference Globe Newswire 5:00 PM

-- February 24, 2026 --

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Globe Newswire 8:45 AM

-- January 21, 2026 --

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers Globe Newswire 8:45 AM

-- January 12, 2026 --

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 Globe Newswire 8:45 AM

-- January 6, 2026 --

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers Globe Newswire 8:45 AM

-- December 18, 2025 --

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 Globe Newswire 8:45 AM

-- December 15, 2025 --

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma Globe Newswire 8:45 AM
Market Data Delayed 15 Minutes